View Older Stories View More Recent Stories

Mar 31, 2025 10:00AM BridgeBio Pharma (BBIO) Reports Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM

Mar 31, 2025 04:15AM Redburn-Atlantic Starts BridgeBio Pharma (BBIO) at Buy

Mar 27, 2025 07:00AM BridgeBio Pharma (BBIO) Announces Beyonttra Approved in Japan to Treat ATTR-CM

Mar 17, 2025 04:01PM BridgeBio Pharma Inc. (BBIO) appoints Thomas Trimarchi as CFO

Mar 17, 2025 07:06AM Cantor Fitzgerald says 15% of biotech companies down 40% or more

Mar 15, 2025 04:00PM Bernstein provides 2025 M&A outlook for U.S. Biotech and Pharma

Mar 10, 2025 08:02AM Deep Track Capital Sends Letter to Dynavax Technologies’ (DVAX) Board

Mar 6, 2025 09:05AM Cantor Fitzgerald Reiterates Overweight Rating on BridgeBio Pharma (BBIO)

Feb 28, 2025 07:50AM BridgeBio Oncology Therapeutics to go Public via Merger with Helix Acquisition Cp II (HLXB)

Feb 24, 2025 04:11PM BridgeBio Pharma (BBIO) Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt

Feb 21, 2025 07:14AM BridgeBio Pharma (BBIO) PT Raised to $52 at Scotiabank

Feb 20, 2025 07:40AM BridgeBio Pharma Inc. (BBIO) Misses Q4 EPS by 27c

Feb 19, 2025 10:00AM Piper Sandler on BridgeBio Pharma (BBIO): 'Survey Suggests Strong Launch Dynamics For Attruby'

Feb 15, 2025 10:00PM Biotech Q4 earnings preview: Goldman Sachs

Feb 12, 2025 07:11AM BridgeBio Pharma (BBIO) PT Raised to $49 at Scotiabank

Feb 11, 2025 09:22AM BridgeBio Pharma Inc. (BBIO) Announces BEYONTTRA Approved by the European Commission to Treat ATTR-CM

Jan 13, 2025 11:00AM BridgeBio Pharma Inc. (BBIO) Announces Commercial Progress, Program Updates, and 2025 Milestones

Jan 2, 2025 12:51PM Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'

Dec 18, 2024 09:08AM Piper Sandler Reiterates Overweight Rating on BridgeBio Pharma (BBIO) Following Key Investor Debate

Dec 16, 2024 06:52AM H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)

Dec 13, 2024 07:19AM BridgeBio Pharma's (BBIO) Acoramidis Receives Positive CHMP Opinion

Nov 25, 2024 09:18AM TD Cowen Reiterates Buy Rating on BridgeBio Pharma (BBIO)

Nov 25, 2024 08:24AM BMO Capital Reiterates Market Perform Rating on BridgeBio Pharma (BBIO)

Nov 25, 2024 08:12AM Piper Sandler Reiterates Overweight Rating on BridgeBio Pharma (BBIO)

Nov 25, 2024 07:13AM BridgeBio Pharma (BBIO): Attruby approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

Nov 25, 2024 06:38AM BridgeBio Pharma (BBIO) PT Raised to $49 at H.C. Wainwright

Nov 22, 2024 04:09PM BridgeBio Pharma Inc. (BBIO) Halted, News Pending

Nov 12, 2024 04:34PM BridgeBio Pharma Inc. (BBIO) Tops Q3 EPS by 13c

Nov 5, 2024 07:30AM BridgeBio Pharma Inc. (BBIO) Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio Management

Oct 24, 2024 10:53AM Citi Reiterates Buy Rating on BridgeBio Pharma (BBIO)

Oct 24, 2024 07:30AM BridgeBio (BBIO) Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024

Oct 2, 2024 06:43AM H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)

Sep 30, 2024 08:25AM BMO Capital Reiterates Market Perform Rating on BridgeBio Pharma (BBIO)

Sep 30, 2024 07:51AM Piper Sandler Reiterates Overweight Rating on BridgeBio Pharma (BBIO)

Sep 30, 2024 07:32AM BridgeBio Pharma (BBIO) Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9

Sep 30, 2024 07:24AM H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)

Sep 24, 2024 08:17AM BMO Capital Reiterates Market Perform Rating on BridgeBio Pharma (BBIO)

Sep 17, 2024 07:31AM BridgeBio Pharma (BBIO) announces FDA has granted Breakthrough Therapy Designation to oral infigratinib

Sep 16, 2024 07:07AM H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)

Sep 11, 2024 07:40AM Piper Sandler Reiterates Overweight Rating on BridgeBio Pharma (BBIO)

Sep 10, 2024 04:45PM BridgeBio Pharma (BBIO) Receives FDA’s Regenerative Medicine Advanced Therapy Designation for BBP-812

Sep 10, 2024 04:45PM BridgeBio Pharma (BBIO) Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy

Sep 3, 2024 07:37AM Oppenheimer Reiterates Perform Rating on Alnylam Pharmaceuticals (ALNY)

Sep 3, 2024 06:54AM Mizuho Reiterates Outperform Rating on BridgeBio Pharma (BBIO)

Sep 3, 2024 06:44AM H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)

Aug 30, 2024 10:57AM TD Cowen Reiterates Buy Rating on BridgeBio Pharma (BBIO)

Aug 30, 2024 10:50AM BridgeBio Pharma (BBIO) Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension

Aug 30, 2024 07:39AM Ainylam Pharmaceuticals shares tumble following study results, BridgeBio Pharma rises

Aug 26, 2024 07:31AM BridgeBio Pharma Inc. (BBIO) Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with M

Aug 19, 2024 07:31AM BridgeBio Pharma Inc. (BBIO) Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia

View More Recent Stories View Older Stories